7:00 a.m. - 7:55 a.m.
SPECIAL SESSION
“Pathophysiology Of Hot Flushes: It’s All In Your Head”
Supported by an educational grant from Wyeth Pharmaceuticals 

10:15 a.m. - 11:00 a.m.
MENOPAUSE DAY DEBATE
"Bioidentical Hormones: Safe Choice Or High Risk For Menopause?” 
Chair: Cynthia K. Sites, M.D. 
Presenters: John E. Buster, M.D. (Con), Nanette F. Santoro, M.D. (Pro)

Needs Assessment: Bioidentical hormones, or those that match the chemical structure of those produced naturally by the body, have been promoted as safer and more effective than traditional menopausal hormones on clinical outcomes such as breast, endometrium, bone, and brain. Although patients are reading more in the lay literature about these products and asking their physicians to prescribe them, physicians often have little information about long term safety and efficacy of these products. A greater understanding of the types and dosages of products available, FDA oversight of them, purity, and their safety and efficacy is needed.

Learning Objectives: At the conclusion of the debate, the participant should be able to:

1. List the evidence supporting the safety and efficacy of bioidentical estrogens and progesterone on breast, endometrium, bone, and brain.

2. Describe the possible risks of using bioidentical hormones.

3. Summarize the gaps in current knowledge about the use of bioidentical estrogens (estradiol, estrone, estriol) and progesterone.

11:00 a.m. - 12:00 p.m.
MENOPAUSE WORKSHOP
"Mock Trial: My Bioidentical Estriol And Progesterone Caused My Breast Cancer” 
Judge: Cynthia K. Sites, M.D.
Plaintiff Attorney: David H. Barad, M.D. 
Defense Attorney: John F. Randolph, Jr., M.D.
Plaintiff: Karen D. Bradshaw, M.D. 
Defendant: Johanna S. Archer, M.D. Jury: Audience

Needs Assessment: Bioidentical hormones, including estradiol, estrone, estriol, and progesterone, have been used in Europe in the past and are now becoming more popular in the United States partly due to increased publicity in the lay press. Women often ask their physicians to prescribe such compounds, and compounding pharmacies are willing to participate. Risks and benefits of these compounds, in particular the risk of breast cancer, is not well understood and will be examined in a mock trial setting.

Learning Objectives: At the conclusion of this mock trial, attendees should be able to:

1. List evidence, pro and con, regarding the possible association of bioidentical hormones use and breast cancer risk.

2. Summarize the evidence regarding use of salivary hormone assays in monitoring levels of bioidentical hormones in post menopausal women.

3. As part of the jury, evaluate the evidence presented to determine if, within a reasonable degree of medical certainty, the bioidentical hormones in this case caused breast cancer.

12:15 p.m. - 1:15 p.m.
MENOPAUSE DAY ROUNDTABLES
Monday
M28. Phytoestrogens And The Climacteric • Cynthia K. Sites, M.D.
M29. Race, Ethnicity And Menopausal Symptoms: Approach To Treatment • David H. Barad, M.D.
M30. Association Of Pelvic Organ Prolapse And Fracture • Lubna Pal, M.D.
M31. Hormone Treatment And Endometrial Safety: Progesterone In The Balance • Veronica A. Ravnikar, M.D.
M32. Androgen Replacement After Menopause • Peter R. Casson, M.D.
M33. Occult Maternal Conditions With Fetal Consequences: What The Infertility Specialist Should Know • Sarah L. Berga, M.D.

1:30 p.m. - 2:15 p.m.
MENOPAUSE DAY KEYNOTE SPEAKER
"The WHI Hormone Therapy Trials: Making Sense Of The Evidence"
JoAnn E. Manson, M.D., Dr.P.H.

3:00 p.m. - 5:00 p.m.
MENOPAUSE ORAL ABSTRACT PRESENTATIONS

5:00 p.m. - 5:30 p.m.
MENOPAUSE SIG MEMBERS MEETING

5:30 p.m. - 7:00 p.m.
MENOPAUSE POSTER PRESENTATIONS & RECEPTION